ThisPROTAC potently and selectively degraded HDAC3 (DC50 =0.042 μM, 14 h treatment) while sparing other HDAC isozymesin a triple-negative breast cancer cell line (MDA-MB-468) and a ER+ breast cancer cell line (T47D). This evidence concerns the gene HDAC3 and breast carcinoma.